Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytopenia 1Primary Myelofibrosis 1Pathologic Complete Response 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 30Carboplatin 13Trastuzumab 8Paclitaxel 7Nivolumab 7Cisplatin 6Ipilimumab 5Cetuximab 5Bevacizumab 5Taxes 4Pemetrexed 4Specimen Handling 3Irinotecan 3Docetaxel 3Cyclophosphamide 3Biopsy 3tisotumab vedotin 2temsirolimus 2spartalizumab 2sargramostim 2pertuzumab 2lenvatinib 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2X-Rays 2Ritonavir 2Psychiatric Rehabilitation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Tretinoin × Thoracic × Clear all
NCT07586826 2026-05-14

N01-A-PICIT-GT

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡